Full Text View
Tabular View
Study Results
Related Studies
Hydroxyurea and Magnesium Pidolate to Treat People With Hemoglobin Sickle Cell Disease
This study has been terminated.
( Enrollment has been terminated due to a slow rate of enrollment. )
Study NCT00532883   Information provided by St. Jude Children's Research Hospital

First Received on September 20, 2007.   Last Updated on January 14, 2013   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Hemoglobin SC Disease
Additional conditions recognized in this trial
Anemia, Sickle Cell
More general conditions related to this trial
Anemia
Anemia, Hemolytic
Anemia, Hemolytic, Congenital
Genetic Diseases, Inborn
Hematologic Diseases
Hemoglobinopathies
Interventions listed in this trial
Hydroxyurea
Magnesium Pidolate
Placebo Pills and Placebo Liquid
More general drug interventions related to this trial
Antineoplastic Agents
Antisickling Agents
Enzyme Inhibitors
Hematologic Agents
Molecular Mechanisms of Pharmacological Action
Nucleic Acid Synthesis Inhibitors
Pharmacologic Actions
Therapeutic Uses
Sponsors listed in this trial
St. Jude Children's Research Hospital
National Heart, Lung, and Blood Institute (NHLBI)


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services